A bipartisan amendment to user fee legislation offers a softer approach to addressing "right to try" concerns related to experimental pharmaceuticals that could defuse the issue during the current session of Congress.
The Senate Committee on Health, Education, Labor and Pensions – which approved the FDA Reauthorization Act by a 21-2 margin...